Wechselwirkungen von Tirzepatid

Hypoglycemia Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see PRECAUTIONS , Drug Interactions ). (Fachinformation zu Chloroquin, Warnhinweise)

Antidiabetic agents Hypoglycemia including fatal outcomes have been reported. (Fachinformation zu Ciprofloxacin, Arzneimittelwechselwirkungen)

Diabetic ketoacidosis should be treated with insulin [see Warnings and Precautions (5.1) and Warnings and Precautions (5.2) ] . (Fachinformation zu Dapagliflozin und Metformin, Gegenanzeigen)

Oral hypoglycemics Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. (Fachinformation zu Fluconazol, Arzneimittelwechselwirkungen)

These conditions should be treated with insulin. (Fachinformation zu Glibenclamid, Gegenanzeigen)

Diabetic ketoacidosis should be treated with insulin. (Fachinformation zu Glipizid und Metformin, Gegenanzeigen)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (Fachinformation zu Hydroxychloroquin, Warnhinweise und Vorsichtsmaßnahmen)

To avoid medication errors between LEVEMIR and other insulins, instruct patients to always check the insulin label before each injection. (Fachinformation zu Insulin detemir, Warnhinweise und Vorsichtsmaßnahmen)

To avoid medication errors between LYUMJEV and other insulins, instruct patients to always check the insulin label before each injection. (Fachinformation zu Insulin lispro, Warnhinweise und Vorsichtsmaßnahmen)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (Fachinformation zu Tirzepatid, Boxed Warning (umrahmter Warnhinweis))

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (Fachinformation zu Tirzepatid, Boxed Warning (umrahmter Warnhinweis))

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (Fachinformation zu Tirzepatid, Boxed Warning (umrahmter Warnhinweis))

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (Fachinformation zu Tirzepatid, Boxed Warning (umrahmter Warnhinweis))

Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (Fachinformation zu Protamin, Boxed Warning (umrahmter Warnhinweis))

Diabetic ketoacidosis should be treated with insulin. (Fachinformation zu Saxagliptin und Metformin, Gegenanzeigen)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (Fachinformation zu Tirzepatid, Boxed Warning (umrahmter Warnhinweis))

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (Fachinformation zu Tirzepatid, Boxed Warning (umrahmter Warnhinweis))

Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required. (Fachinformation zu Abirateron, Warnhinweise und Vorsichtsmaßnahmen)

When such drugs are withdrawn from patients receiving acarbose tablets in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia. (Fachinformation zu Acarbose, Arzneimittelwechselwirkungen)

Diabetes and Hypoglycemia β-blockers may potentiate insulin-induced hypoglycemia and mask some of its manifestations such as tachycardia; however, dizziness and sweating are usually not significantly affected. (Fachinformation zu Acebutolol, Warnhinweise)

Consideration should be taken in patients being treated with antidiabetic agents. (Fachinformation zu Acetazolamid, Arzneimittelwechselwirkungen)

Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. (Fachinformation zu Acetylsalicylsäure und Dipyridamol, Arzneimittelwechselwirkungen)

Glyburide: In a trial of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose-lowering effect of glyburide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects. (Fachinformation zu Acitretin, Arzneimittelwechselwirkungen)

Alkohol kann zusammen mit Insulin oder Sulfonylharnstoffen einen niedrigen Blutzucker verursachen, und starker Alkoholkonsum zusammen mit Metformin erhöht das Risiko einer Laktatazidose. (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (Fachinformation zu Alogliptin, Warnhinweise und Vorsichtsmaßnahmen)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin and metformin HCl tablets. (Fachinformation zu Alogliptin und Metformin, Warnhinweise und Vorsichtsmaßnahmen)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (Fachinformation zu Amlodipin und Benazepril, Arzneimittelwechselwirkungen)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Fachinformation zu Atazanavir, Warnhinweise und Vorsichtsmaßnahmen)

At recommended doses atenolol does not potentiate insulin-induced hypoglycemia and, unlike nonselective beta- blockers, does not delay recovery of blood glucose to normal levels. (Fachinformation zu Atenolol und Chlortalidon, Warnhinweise)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (Fachinformation zu Benazepril, Arzneimittelwechselwirkungen)

Antidiabetic agents: Dosage adjustment of antidiabetic drug may be required. (Fachinformation zu Benazepril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Unlike nonselective beta-blockers, betaxolol does not prolong insulin-induced hypoglycemia. (Fachinformation zu Betaxolol, Warnhinweise)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Fachinformation zu Bexagliflozin, Warnhinweise und Vorsichtsmaßnahmen)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Fachinformation zu Bexaroten, Warnhinweise und Vorsichtsmaßnahmen)

Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. (Fachinformation zu Bisoprolol, Warnhinweise)

Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. (Fachinformation zu Bisoprolol und Hydrochlorothiazid, Warnhinweise)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Brimonidin und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules exceeds maximum recommended daily dosage. (Fachinformation zu Butalbital, Acetylsalicylsäure und Koffein, Arzneimittelwechselwirkungen)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (Fachinformation zu Butalbital, Acetylsalicylsäure, Koffein und Codein, Arzneimittelwechselwirkungen)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (Fachinformation zu Canagliflozin, Warnhinweise und Vorsichtsmaßnahmen)

Antidiabetic drugs (oral agents and insulin) − Dosage adjustment of the antidiabetic drug may be required. (Fachinformation zu Candesartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Closely monitor for adverse reactions of CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions when used concomitantly with XELODA (e.g., anticoagulants, antidiabetic drugs). (Fachinformation zu Capecitabin, Arzneimittelwechselwirkungen)

During the 8-week trial, serum insulin levels increased by 12 pmol/L in the VRAYLAR 1 mg to 2 mg per day group, 20 pmol/L in the VRAYLAR 2 mg to 4.5 mg per day group, and 8.5 pmol/L in the placebo group. (Fachinformation zu Cariprazin, Warnhinweise und Vorsichtsmaßnahmen)

Insulin and oral hypoglycemics action may be enhanced. (Fachinformation zu Carvedilol, Arzneimittelwechselwirkungen)

Hypoglycemia Quinine stimulates release of insulin from the pancreas, and patients, especially pregnant women, may experience clinically significant hypoglycemia. (Fachinformation zu Chinin, Warnhinweise und Vorsichtsmaßnahmen)

Antidiabetic Drugs (Oral Agents and Insulin) - dosage adjustment of the antidiabetic drug may be required. (Fachinformation zu Chlorothiazid, Arzneimittelwechselwirkungen)

Oral Hypoglycemic Agents/Insulin: The concomitant use of clarithromycin tablets and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. (Fachinformation zu Clarithromycin, Warnhinweise und Vorsichtsmaßnahmen)

…placebo) and when colesevelam hydrochloride was used in combination with pioglitazone (median increase 11% compared to placebo in combination with pioglitazone), sulfonylureas (median increase 18% compared to placebo in combination with sulfonylureas), and insulin (median increase 22% compared to placebo in combination with insulin) [see Adverse Reactions (6.1) ]. (Fachinformation zu Colesevelam, Warnhinweise und Vorsichtsmaßnahmen)

Caution should be exercised when used with antidiabetic drugs. (Fachinformation zu Danazol, Arzneimittelwechselwirkungen)

• Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with DAPAGLIFLOZIN TABLETS. (Fachinformation zu Dapagliflozin, Warnhinweise und Vorsichtsmaßnahmen)

Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. (Fachinformation zu Darunavir, Warnhinweise und Vorsichtsmaßnahmen)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Fachinformation zu Darunavir und Cobicistat, Warnhinweise und Vorsichtsmaßnahmen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (Fachinformation zu Dexamethason, Warnhinweise und Vorsichtsmaßnahmen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (Fachinformation zu Dulaglutid, Warnhinweise und Vorsichtsmaßnahmen)

The effects of increases in the concentration of the progestational component norgestimate are not fully known and can include increased risk of insulin resistance, dyslipidemia, acne, and venous thrombosis. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

Hypoglycemia: Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia. (Fachinformation zu Empagliflozin, Warnhinweise und Vorsichtsmaßnahmen)

Hypoglycemia: Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia. (Fachinformation zu Empagliflozin und Metformin, Warnhinweise und Vorsichtsmaßnahmen)

Anti-diabetic drugs (oral agents and insulin) Dosage adjustment of the anti-diabetic drug may be required. (Fachinformation zu Enalapril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (Fachinformation zu Exenatid, Warnhinweise und Vorsichtsmaßnahmen)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (Fachinformation zu Fludrocortison, Arzneimittelwechselwirkungen)

As is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued. (Fachinformation zu Fluoxetin, Warnhinweise und Vorsichtsmaßnahmen)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Fachinformation zu Fosamprenavir, Warnhinweise und Vorsichtsmaßnahmen)

Insulin requirements in diabetic patients may be increased, decreased, or unchanged. (Fachinformation zu Fosinopril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (Fachinformation zu Tirzepatid, Warnhinweise und Vorsichtsmaßnahmen)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (Fachinformation zu Tirzepatid, Warnhinweise und Vorsichtsmaßnahmen)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (Fachinformation zu Tirzepatid, Warnhinweise und Vorsichtsmaßnahmen)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

For patients with type 2 diabetes mellitus, oral antidiabetic treatment dosage modifications may be needed. (Fachinformation zu Humaninsulin (Normalinsulin), Warnhinweise und Vorsichtsmaßnahmen)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (Fachinformation zu Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Antidiabetic Agents Clinical Impact: Corticosteroids in supraphysiologic doses may increase blood glucose concentrations. (Fachinformation zu Hydrocortison, Arzneimittelwechselwirkungen)

Hydroxyurea may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems and may lead to hypoglycemia if sensor glucose results are relied upon to dose insulin. (Fachinformation zu Hydroxycarbamid, Warnhinweise und Vorsichtsmaßnahmen)

Increase frequency of glucose monitoring with changes to: insulin dosage, concomitantly administered glucose lowering medications, meal pattern, physical activity; and in patients with renal or hepatic impairments and hypoglycemia unawareness ( 5. (Fachinformation zu Insulin aspart, Warnhinweise und Vorsichtsmaßnahmen)

The risk of hypoglycemia after an injection is related to the duration of action of the insulin [see Clinical Pharmacology ( 12.2 )] and, in general, is highest when the glucose lowering effect of the insulin is maximal. (Fachinformation zu Insulin degludec, Warnhinweise und Vorsichtsmaßnahmen)

For patients with type 2 diabetes, dosage adjustments of concomitant oral and antidiabetic products may be needed. (Fachinformation zu Insulin glargin, Warnhinweise und Vorsichtsmaßnahmen)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (Fachinformation zu Irbesartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Antidiabetic Drugs Repaglinide Saxagliptin Monitor for adverse reactions. (Fachinformation zu Itraconazol, Arzneimittelwechselwirkungen)

Antidiabetics repaglinide, saxagliptin Antihelmintics and Antiprotozoals praziquantel Antimigraine Drugs ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine) eletriptan Ergot alkaloids: The potential increase in plasma concentrations of ergot alkaloids when coadministered with ketoconazole tablets… (Fachinformation zu Ketoconazol, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Fachinformation zu Lanreotid, Warnhinweise und Vorsichtsmaßnahmen)

Blood Glucose Disturbances Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (Fachinformation zu Levofloxacin, Warnhinweise und Vorsichtsmaßnahmen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (Fachinformation zu Linagliptin, Warnhinweise und Vorsichtsmaßnahmen)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating JENTADUETO XR. (Fachinformation zu Linagliptin und Metformin, Warnhinweise und Vorsichtsmaßnahmen)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (Fachinformation zu Linezolid, Warnhinweise und Vorsichtsmaßnahmen)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (Fachinformation zu Liraglutid, Warnhinweise und Vorsichtsmaßnahmen)

Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (Fachinformation zu Lisinopril, Arzneimittelwechselwirkungen)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Fachinformation zu Lisinopril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Fachinformation zu Lopinavir und Ritonavir, Warnhinweise und Vorsichtsmaßnahmen)

Antidiabetic drugs: dosage adjustment of antidiabetic may be required. (Fachinformation zu Losartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues : Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. (Fachinformation zu Metformin, Warnhinweise und Vorsichtsmaßnahmen)

Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (Fachinformation zu Methylprednisolon, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Insulin Clinical Impact Increased GI motility by metoclopramide may increase delivery of food to the intestines and increase blood glucose. (Fachinformation zu Metoclopramid, Arzneimittelwechselwirkungen)

Insulin And Oral Antidiabetic Agents See Glucose Tolerance under PRECAUTIONS , General . (Fachinformation zu Metolazon, Arzneimittelwechselwirkungen)

Antidiabetic drugs: Dosage adjustment may be required. (Fachinformation zu Metoprolol und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Antidiabetic agents Carefully monitor blood glucose. (Fachinformation zu Moxifloxacin, Arzneimittelwechselwirkungen)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (Fachinformation zu Nadolol, Warnhinweise)

Use of Antidiabetic Medications: Weight loss may cause hypoglycemia. (Fachinformation zu Naltrexon und Bupropion, Warnhinweise und Vorsichtsmaßnahmen)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (Fachinformation zu Tirzepatid, Warnhinweise und Vorsichtsmaßnahmen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (Fachinformation zu Ofloxacin, Warnhinweise)

• Antidiabetic drugs: Dosage adjustment may be required. (Fachinformation zu Olmesartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (Fachinformation zu Olmesartan, Amlodipin und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

A reduction in dose of oral hypoglycemic medication (e.g., sulfonylureas) or insulin may be required in some patients [see Clinical Studies (14) ] . (Fachinformation zu Orlistat, Warnhinweise und Vorsichtsmaßnahmen)

• A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fachinformation zu Phentermin, Warnhinweise und Vorsichtsmaßnahmen)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (Fachinformation zu Pindolol, Warnhinweise)

Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. (Fachinformation zu Pioglitazon, Warnhinweise und Vorsichtsmaßnahmen)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (Fachinformation zu Tirzepatid, Warnhinweise und Vorsichtsmaßnahmen)

Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. (Fachinformation zu Pioglitazon und Metformin, Warnhinweise und Vorsichtsmaßnahmen)

Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (Fachinformation zu Prednisolon, Arzneimittelwechselwirkungen)

Antidiabetic agents: May increase blood glucose concentrations. (Fachinformation zu Prednison, Arzneimittelwechselwirkungen)

Monitor patients for the development of edema when co-administering LYRICA CR and thiazolidinedione antidiabetic agents. (Fachinformation zu Pregabalin, Warnhinweise und Vorsichtsmaßnahmen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (Fachinformation zu Tirzepatid, Warnhinweise und Vorsichtsmaßnahmen)

Decrease exposure Digitoxin Decrease exposure Fluoroquinolones Pefloxacin Administered with rifampin 900 mg daily Decrease exposure Moxifloxacin , Decrease exposure Oral Hypoglycemic Agents (e.g., sulfonylureas) Glyburide Decrease exposure Rifampin may worsen glucose control of glyburide. (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

…Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines… (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Fachinformation zu Ritonavir, Warnhinweise und Vorsichtsmaßnahmen)

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (Fachinformation zu Salsalat, Arzneimittelwechselwirkungen)

• Hypoglycemia with Concomitant Use of Insulin or Insulin Secretagogues: Consider a lower dosage of insulin or insulin secretagogue when used in combination wtih Saxagliptin tablets ( 5.3 ) (Fachinformation zu Saxagliptin, Warnhinweise und Vorsichtsmaßnahmen)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin : May increase the risk of hypoglycemia, including severe hypoglycemia. (Fachinformation zu Semaglutid, Warnhinweise und Vorsichtsmaßnahmen)

Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. (Fachinformation zu Sitagliptin, Warnhinweise und Vorsichtsmaßnahmen)

Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. (Fachinformation zu Sitagliptin und Metformin, Warnhinweise und Vorsichtsmaßnahmen)

Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (Fachinformation zu Somatropin, Warnhinweise und Vorsichtsmaßnahmen)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (Fachinformation zu Sotalol, Arzneimittelwechselwirkungen)

Antidiabetic drugs (e.g., oral agents, insulin): Dosage adjustment of the antidiabetic drug may be required (see Precautions ). (Fachinformation zu Spironolacton und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (Fachinformation zu Sulfamethoxazol und Trimethoprim (Cotrimoxazol), Arzneimittelwechselwirkungen)

• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Fachinformation zu Sunitinib, Warnhinweise und Vorsichtsmaßnahmen)

Antidiabetic drugs: Dosage adjustment may be required ( 7.6 ) (Fachinformation zu Telmisartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Fachinformation zu Temsirolimus, Warnhinweise und Vorsichtsmaßnahmen)

Insulin: In patients with diabetes, concomitant use with TLANDO may decrease blood glucose and insulin requirements ( 7.1) . (Fachinformation zu Testosteron, Arzneimittelwechselwirkungen)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Fachinformation zu Timolol, Warnhinweise und Vorsichtsmaßnahmen)

(See PRECAUTIONS . ) Antidiabetic Agents Concomitant use of ACE inhibitors and antidiabetic medicines (insulin or oral hypoglycemic agents) may cause an increased blood glucose lowering effect with greater risk of hypoglycemia. (Fachinformation zu Trandolapril, Arzneimittelwechselwirkungen)

Hypoglycemia in Diabetic Patients Some MAOIs have contributed to hypoglycemic episodes in diabetic patients receiving insulin or other blood-glucose-lowering agents. (Fachinformation zu Tranylcypromin, Warnhinweise und Vorsichtsmaßnahmen)

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (Fachinformation zu Triamcinolon, Arzneimittelwechselwirkungen)

Infusion of glucose and insulin has also been used to treat hyperkalemia. (Fachinformation zu Triamteren, Warnhinweise und Vorsichtsmaßnahmen)

Oral Hypoglycemic Drugs Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (Fachinformation zu Triamteren und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Hydrochlorothiazide: When administered concurrently, the following drugs may interact with thiazide diuretics: Antidiabetic Drugs (oral agents and insulin) - Dosage adjustment of the antidiabetic drug may be required. (Fachinformation zu Valsartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

• Effect of Smoking Cessation on Other Drugs: Pharmacokinetics or pharmacodynamics of certain drugs (e.g., theophylline, warfarin, insulin) may be altered, necessitating dose adjustment. (Fachinformation zu Vareniclin, Arzneimittelwechselwirkungen)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. (Fachinformation zu Voriconazol, Arzneimittelwechselwirkungen)

Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with ZEPBOUND. (Fachinformation zu Tirzepatid, Arzneimittelwechselwirkungen)

Antidiabetic drug requirements (i.e., insulin) may be altered. (Fachinformation zu Amfepramon, Arzneimittelwechselwirkungen)

Such measures include the intravenous administration of sodium bicarbonate solution or oral or parenteral glucose with a rapid-acting insulin preparation. (Fachinformation zu Amilorid, Warnhinweise)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (Fachinformation zu Bupropion, Warnhinweise und Vorsichtsmaßnahmen)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (Fachinformation zu Clozapin, Warnhinweise und Vorsichtsmaßnahmen)

Hyperglycemia Hyperglycemia, resulting from the inhibitory effect of phenytoin (the active metabolite of CEREBYX) on insulin release, has been reported. (Fachinformation zu Fosphenytoin, Warnhinweise und Vorsichtsmaßnahmen)

Oral Hypoglycemic Agents In pharmacokinetic studies of lovastatin in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY , Clinical Studies in Adults ). (Fachinformation zu Lovastatin, Arzneimittelwechselwirkungen)

In an uncontrolled open-label trial of CAPLYTA for up to 1 year in adult patients with stable schizophrenia, the percentages of patients with shifts in fasting glucose and insulin values from normal to high were 8% and 12%, respectively. (Fachinformation zu Lumateperon, Warnhinweise und Vorsichtsmaßnahmen)

Administer INCRELEX shortly before or after a meal or snack, because it has insulin-like hypoglycemic effects. (Fachinformation zu Mecasermin, Warnhinweise und Vorsichtsmaßnahmen)

Insulin requirements in diabetes mellitus may be altered in association with the use of methamphetamine and the concomitant dietary regimen. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out. (Fachinformation zu Miconazol, Arzneimittelwechselwirkungen)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (Fachinformation zu Milrinon, Arzneimittelwechselwirkungen)

Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (Fachinformation zu Moexipril, Arzneimittelwechselwirkungen)

Glucose Lowering Drugs Pioglitazone: Co-administration of pioglitazone for 7 days with 30 mg nifedipine ER administered orally q.d. for 4 days to male and female volunteers resulted in least square mean (90% CI) values for unchanged nifedipine of 0.83 (0.73-0.95) for C max and 0.88 (0.80-0.96) for AUC relative to nifedipine monotherapy. (Fachinformation zu Nifedipin, Vorsichtsmaßnahmen)

Insulin and Oral Hypoglycemic Medications Requirements may be altered. (Fachinformation zu Phendimetrazin, Arzneimittelwechselwirkungen)

Hyperglycemia Hyperglycemia, resulting from the drug’s inhibitory effects on insulin release, has been reported. (Fachinformation zu Phenytoin, Warnhinweise und Vorsichtsmaßnahmen)

…been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine,… (Fachinformation zu Prazosin, Arzneimittelwechselwirkungen)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (Fachinformation zu Sulfadiazin, Arzneimittelwechselwirkungen)

Administration of intravenous calcium, bicarbonate, and glucose with insulin, with hyperventilation have resulted in successful resuscitation in some of the reported cases. (Fachinformation zu Suxamethonium, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (Fachinformation zu Telmisartan und Amlodipin, Arzneimittelwechselwirkungen)

Hypoglycemic Agents: In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. (Fachinformation zu Tolmetin, Arzneimittelwechselwirkungen)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (Fachinformation zu Ziprasidon, Warnhinweise und Vorsichtsmaßnahmen)

Glyburide Clinical Impact: While oxaprozin does alter the pharmacokinetics of glyburide, coadministration of oxaprozin to type II non-insulin dependent diabetic patients did not affect the area under the glucose concentration curve nor the magnitude or duration of control. (Fachinformation zu Oxaprozin, Arzneimittelwechselwirkungen)

Oral hypoglycemic agents Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily, have shown no clinically significant interaction with oral hypoglycemic agents. (Fachinformation zu Sulindac, Arzneimittelwechselwirkungen)

Other interactions: Vardenafil hydrochloride tablets had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters). (Fachinformation zu Vardenafil, Arzneimittelwechselwirkungen)